Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
BACKGROUND
Clinical experience with the radiolabeled somatostatin analogues 90Y-DOTATOC and, more recently, 177Lu-DOTATATE, is ongoing since more than a decade in few centers. Dosimetric studies demonstrated that 90Y-DOTATOC and 177Lu-DOTATATE are able to deliver high doses to somatostatin receptor sst2-expressing tumors and low doses to normal organs.


CONCLUSIONS
Clinical studies demonstrated that partial and complete objective responses in up to 30% of patients can be obtained, with a great survival benefit in treated patients. Side effects may involve the kidney and the bone marrow and are usually mild. Renal protection is used to minimize the risk of a late decrease of renal function.
Bodei
L
L
Nuclear Medicine Divisions, European Instituteof Oncology, Milano, Italy.
Pepe
G
G
Paganelli
G
G
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008187:Lutetium / Q000627:therapeutic use; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives / Q000627:therapeutic use; D011868:Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D018000:Receptors, Peptide / Q000187:drug effects*; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015021:Yttrium Radioisotopes / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide; D015021:Yttrium Radioisotopes; D013004:Somatostatin; D008187:Lutetium; D015282:Octreotide; C106246:Edotreotide